Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Markets Downgrades Regeneron Pharma (REGN) to Neutral
-
Streetinsider.com's Hot Lunchtime Reads 8/27: (TSLA) (RJET) (QURE) (WSM)
-
Chardan Capital Trims PT on uniQure (QURE) to $35; Notes Uncertainty of Glybera in the U.S.
-
Chardan Capital Markets Reiterates Buy on CEVA, Inc. (CEVA) Ahead of Galaxy Note 5 and S6 Edge+ Launch
-
Chardan Capital Affirms Esperion (ESPR) at 'Sell'; Bear Case Confirmed, CVOT Needed for P2 Indications
-
Chardan Capital Markets, LLC Expands Global Platform With The Appointment Of George Nikitiadis As Managing Director And Head Of The International Portfolio Team In New York
-
REGENXBIO (RGNX) Files for $100M Common Stock IPO
-
Pre-Open Stock Movers 08/17: (AVEO) (ZU) (KITE) (TSLA) Higher; (ONTX) (MU) (EL) Lower (more...)
-
UPDATE: Chardan Upgrades Avalanche Biotechnologies (AAVL) to Buy
-
YOU On Demand (YOD) has Another Impressive Quarter; Chardan Capital Affirms 'Buy' Rating
-
Unique Fabricating, Inc. Reports Second Quarter Revenues of $35.7 Million; Diluted Earnings Per Share of $0.24
-
Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002
-
Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
-
RADA Announces Closing of Public Offering of Its Ordinary Shares
-
Chardan Capital Sees Himax (HIMX) Missing Q3 Revenue Estimates; Offers Update
-
Chardan Releases Industry Report Covering PharmaCyte Biotech
-
Chardan Capital Affirms Axovant Sciences (AXON) at 'Sell'; Sees as Mispriced Following vTv Therapeutics (VTVT) IPO
-
Chardan Capital Markets, LLC Expands Equity Division With Appointment Of Jeff Sklar, Managing Director and Head Of Institutional Sales
-
Chardan Capital Markets Starts MassRoots (MSRT) at Buy; Largest Social Network for Cannabis Community
-
Chardan Capital Boosts PT on Esperion (ESPR) to $45; New Disclosure Does Not Reveal Higher Rate of SAEs for ETC-1002
-
EyeGate (EYEG) Prices $10M Offering of Common Stock and Warrants
-
RADA Electronic Industries (RADA) 6.9M Stock Offering Prices at $1.23/Share
-
RADA Announces Pricing Of Public Offering Of Its Ordinary Shares
-
EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
-
EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
-
Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors
-
Chardan Capital Sees Axovant's (AXON) RVT-101 Only Costing $5M Upfront; 'Sell' Rating Affirmed
-
Esperion Therapeutics (ESPR) PT Cut to $40 at Chardan Capital Markets
-
VistaGen Therapeutics (VSTA) Highlighted at Chardan Capital After Allergan Acquires Comp Naurex
-
IDI, Inc. Announces $10 Million Registered Direct Offering
-
Chardan Capital Trims PT on Axovant (AXON) to $9.50; News is Good, but 24+ Late-Stage Alzheimer's Drugs in Development
-
Chardan Capital Markets Starts Applied Genetic Technologies Corp. (AGTC) at Buy
-
Notable Analyst Rating Changes 7/15: (GES) (CSX) (LNKD) Upgraded; (LLY) (LPLA) (CINF) Downgraded
-
OncoCyte Announces Appointment of Andy Arno to Board of Directors
-
Chardan Capital Markets Starts Energous Corp (WATT) at Buy; Apple, LG, Microsoft or Samsung Seen as Tier 1 Customer
-
MassRoots Closes $1 Million Financing Round
-
PlacementTracker Publishes First Half 2015 PIPE Market League Tables
-
Chardan Capital Says Esperion Therapeutics (ESPR) Concerns 'Unanswered' Despite Lifting of FDA Hold
-
Market Wrap: Horizon Pharma Gets Hostile on Depomed; Tesla Slumps on Downgrade; U.S. Trade Deficit Widens in May
-
Unusual 11 Mid-Day Movers 7/7: (DEPO) (PBMD) (IPDN) Higher; (ETRM) (STV) (BZUN) Lower
-
Chardan Capital Markets Announces Hiring of Andy Arno to The Special Equities Group
-
Chardan Capital Markets Remains Bullish Following Digital Ally (DGLY) Q2 Pre-Release
-
Digital Ally (DGLY) Prelim. Q2 Results Outpace, But Chardan Capital Remains Skeptical on FY15 Op. Income Outlook
-
Pre-Open Stock Movers 07/07: (DEPO) (PBMD) (PNK) Higher; (ETRM) (AMD) (SHLM) Lower (more...)
-
UPDATE: Chardan Upgrades Himax (HIMX) to Buy Ahead of Microsoft's (MSFT) Announcement on Hololens Availability
-
La Jolla Pharma (LJPC) PT Raised to $60 at Chardan Capital Markets
-
Streetinsider.com's Hot Lunchtime Reads 7/2: (VRTX) (TWTR) (AMD) (MDCO) (AMBA)
-
Vislab Adds Computer Vision to Ambarella's (AMBA) Portfolio; Chardan Affirms at 'Neutral'
-
Viggle Announces the Closing of a $4.2 Million Underwritten Sale of Common Stock to a Single Institutional Investor
-
Viggle (VGGL) Prices 2.05M Common Stock Offering $2.05/Share

